CDS cells were found to be more sensitive to the dual PI3K/mTOR inhibitor NVP-BEZ235 (40), which has been reported as a promising candidate for the treatment of sarcoma (40, 41), than to other selective PI3K, AKT, and mTOR inhibitors (such as alpelisib, MK-2206, capivasertib and everolimus) or multi-kinase inhibitors (such as pazopanib, ponatinib, nilotinib). This evidence concerns the gene AKT1 and sarcoma.